INT platelet set-small, part no INT2130B
Ended Purchase Order Awarded Last action
- Contract number
- N0025921P0334
- Awardee
-
Cerus Corporation UEI KJJQRRLY2FL5
- Awarding agency
-
Bureau of Medicine and Surgery
Department of the Navy, Department of Defense
- Obligated
- $0
Award facts
- Contract value 0% obligated
- $218,371.20 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Concord, CA 94520, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $74,230 | |
| Exercise an Option | $0 | |
| Funding Only Action | $72,781 | |
| Exercise an Option | $0 | |
| Funding Only Action | $71,360 | |
| Original award | $0 |
About this award
Cerus Corporation received a firm fixed-price purchase order from the Defense Health Agency (DHA) on August 27, 2021, for INTERCEPT Platelet Set-Small units (Part No. INT2130B), with a ceiling value of $218,371.20 and an ultimate completion date of October 1, 2024. The contract was awarded without a set-aside designation and will be performed in Concord, California, where Cerus maintains its headquarters. Cerus Corporation specializes in blood safety technologies and pathogen reduction systems, with the INTERCEPT Blood System representing its flagship product line that uses riboflavin and ultraviolet light technology to inactivate pathogens in blood components including platelets and plasma.
This award reflects the DHA's continued procurement of critical blood safety products for military medical facilities. Cerus Corporation has established itself as a primary vendor to the DHA and National Institutes of Health Clinical Center through multiple contracts centered on INTERCEPT technology, with many awards structured as sole-source purchases due to the company's unique technological capabilities. The platelet processing sets acquired under this contract support the enhanced safety of blood products used in medical transfusions across military healthcare facilities, contributing to DHA's broader mission of providing advanced medical countermeasures and reducing transfusion-transmitted infection risks for military personnel and beneficiaries.
Quick answers
Who was awarded contract N0025921P0334?
N0025921P0334 was awarded to Cerus Corporation by Bureau of Medicine and Surgery (Department of the Navy) on August 27, 2021.
How much is contract N0025921P0334 worth?
The government has obligated $0 on N0025921P0334. Its current value, with exercised options, is $218,371.
Which agency awarded contract N0025921P0334?
Bureau of Medicine and Surgery (Department of the Navy) awarded N0025921P0334, with funding from Defense Health Agency (Department of Defense).
Was contract N0025921P0334 competed?
The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award